Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pharmaswiss Česká republika s.r.o. - brimonidin; timolol - kapljice za oko, raztopina - brimonidin 1,3 mg / 1 ml  timolol5 mg / 1 ml; timolol 5 mg / 1 ml - timolol, kombinacije

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lenis d.o.o. - klofazimin - kapsula, mehka - klofazimin 50 mg / 1 kapsula - klofazimin

Evropska unija - slovenščina - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - cistična fibroza - drugi proizvodi dihal - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 in 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 in 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Evropska unija - slovenščina - EMA (European Medicines Agency)

teva b.v. - colistimethate natrijev - cistična fibroza - antibacterials za sistemsko uporabo, - colobreathe je navedeno za upravljanje kronične pljučne okužbe zaradi pseudomonas aeruginosa pri bolnikih s cistično fibrozo (cf), starih šest let in starejši. upoštevati je treba uradne smernice za ustrezno uporabo protibakterijsko agenti.

Evropska unija - slovenščina - EMA (European Medicines Agency)

pacira limited - citarabin - meningealne neoplazme - antineoplastična sredstva - intratekalno zdravljenje limfomatoznega meningitisa. pri večini bolnikov bo takšno zdravljenje del simptomatske paliacije bolezni.

Evropska unija - slovenščina - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cistična fibroza - drugi proizvodi dihal - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

intervet international -

Evropska unija - slovenščina - EMA (European Medicines Agency)

sanofi pasteur msd, snc - polyribosylribitol fosfat iz haemophilus influenzae tipa b, kot prp-ompc, zunanja membrana, beljakovine kompleks neisseria meningitidis (zunanje membrane protein complex v b11 sev neisseria meningitidis podskupini b), adsorbira hepatitis b surface antigen, proizvedene v rekombinantne kvasovke celic (saccharomyces cerevisiae) - hepatitis b; meningitis, haemophilus; immunization - cepiva - procomvax je indicirano za cepljenje proti invazivni bolezni, ki povzroča haemophilus influenzae tipa b in proti okužbi, zaradi vseh znanih podtipov virusa hepatitisa b pri dojenčkih 6 tednov do 15 mesecev starosti.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ena viala liofilizirano komponento ki vsebuje živ -

Evropska unija - slovenščina - EMA (European Medicines Agency)

novartis europharm limited  - voretigene neparvovec - leber congenital amaurosis; retinitis pigmentosa - other ophthalmologicals - luxturna je indiciran za zdravljenje odraslih in pediatričnih bolnikih z izgubo vida zaradi dedne očesne mrežnice distrofija, ki jih povzročajo potrdili biallelic rpe65 mutacije in ki imajo dovolj preživetja celic mrežnice.